Aperio opens operations center in Australia and New Zealand in response to global demand for digital pathology systems and services
Vista, Calif. (BUSINESS WIRE) - Aperio Technologies, Inc., a global leader in digital pathology systems and services for the healthcare and life sciences industry, is pleased to announce the formation of its Australian and New Zealand operations center, headquartered in Brisbane. Bolstered by increasing demand for the company's digital pathology solutions, Aperio's expansion will be led by Howard Powell, national sales director, and will focus on providing sales, service, and marketing support across Australia and New Zealand.
This expansion is the latest in Aperio's plans for continued global growth and the delivery of digital pathology solutions to customers worldwide. Aperio currently has an installed base of more than 375 systems in 25 countries, including more than two-thirds of the top 15 rated U.S. hospitals, leading academic medical centers and reference laboratories, and two-thirds of the top 15 pharmaceutical companies.
"In the last fiscal year, Aperio experienced more than 125% sales growth, an impressive figure that demonstrates how the emerging digital pathology market is resonating both nationally and globally," said Dirk Soenksen, CEO of Aperio. "We are committed to building upon our success by selectively expanding Aperio's global footprint in order to maximize our ability to understand and serve customers."
Aperio's digital pathology solutions enable users to achieve greater efficiency and cost savings by improving workflow processes and expanding data access, integration and reporting capabilities. Aperio's patented linear array-based ScanScope slide scanning systems are offered with Spectrum information management software to enable the viewing, analysis and management of digital slides and other images in a secure multi-user, multi-site environment, from anywhere, anytime.
The nature of Australia's geography, with its large land mass separating numerous population centers, facilitates real time remote viewing and evaluation of digital slides by pathology experts, one of the key value propositions for digital pathology. The Royal College of Pathologists of Australia (RCPA), the official body governing the practice of pathology in Australia, is routinely using Aperio's ScanScope system to conduct proficiency testing throughout the country.
About Aperio
Aperio is digitizing pathology. We provide systems and services for digital pathology, which is an environment for the management and interpretation of pathology information that originates with the digitization of a glass slide. Aperio's award-winning ScanScope slide scanning systems and Spectrum? digital pathology information management software improve the efficiency and quality of pathology services for pathologists and other professionals.
Applications include education, remote viewing, archival and retrieval, basic research, and image analysis. Aperio's products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For more information, please visit www.aperio.com.
Aperio
Kevin Whiteley, 760-539-1177 Vice President, Marketingkwhiteley@aperio.com
or Myla Wagner Public Relations
Myla Wagner, 925-736-7515 myla@mylawagnerpr.com
Vista, Calif. (BUSINESS WIRE) - Aperio Technologies, Inc., a global leader in digital pathology systems and services for the healthcare and life sciences industry, is pleased to announce the formation of its Australian and New Zealand operations center, headquartered in Brisbane. Bolstered by increasing demand for the company's digital pathology solutions, Aperio's expansion will be led by Howard Powell, national sales director, and will focus on providing sales, service, and marketing support across Australia and New Zealand.
This expansion is the latest in Aperio's plans for continued global growth and the delivery of digital pathology solutions to customers worldwide. Aperio currently has an installed base of more than 375 systems in 25 countries, including more than two-thirds of the top 15 rated U.S. hospitals, leading academic medical centers and reference laboratories, and two-thirds of the top 15 pharmaceutical companies.
"In the last fiscal year, Aperio experienced more than 125% sales growth, an impressive figure that demonstrates how the emerging digital pathology market is resonating both nationally and globally," said Dirk Soenksen, CEO of Aperio. "We are committed to building upon our success by selectively expanding Aperio's global footprint in order to maximize our ability to understand and serve customers."
Aperio's digital pathology solutions enable users to achieve greater efficiency and cost savings by improving workflow processes and expanding data access, integration and reporting capabilities. Aperio's patented linear array-based ScanScope slide scanning systems are offered with Spectrum information management software to enable the viewing, analysis and management of digital slides and other images in a secure multi-user, multi-site environment, from anywhere, anytime.
The nature of Australia's geography, with its large land mass separating numerous population centers, facilitates real time remote viewing and evaluation of digital slides by pathology experts, one of the key value propositions for digital pathology. The Royal College of Pathologists of Australia (RCPA), the official body governing the practice of pathology in Australia, is routinely using Aperio's ScanScope system to conduct proficiency testing throughout the country.
About Aperio
Aperio is digitizing pathology. We provide systems and services for digital pathology, which is an environment for the management and interpretation of pathology information that originates with the digitization of a glass slide. Aperio's award-winning ScanScope slide scanning systems and Spectrum? digital pathology information management software improve the efficiency and quality of pathology services for pathologists and other professionals.
Applications include education, remote viewing, archival and retrieval, basic research, and image analysis. Aperio's products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For more information, please visit www.aperio.com.
Aperio
Kevin Whiteley, 760-539-1177 Vice President, Marketingkwhiteley@aperio.com
or Myla Wagner Public Relations
Myla Wagner, 925-736-7515 myla@mylawagnerpr.com
No comments:
Post a Comment